Conclusion: Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir probably decreases the risk of symptomatic seasonal influenza in individuals at high risk for severe disease after exposure to seasonal influenza viruses. Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir might reduce the risk of symptomatic zoonotic influenza after exposure to novel influenza A viruses associated with severe disease in infected humans.
PubMed 39181596 ↗Amantadine
The short answer. There isn't much data on Amantadine yet — 21 mentions, 5 with a clear outcome — so treat these numbers as anecdotal. It is well studied — 147 meta-analyses on PubMed.
From 21 mentions in total — the rest didn't say how it went and aren't counted.
What Amantadine does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 147 meta-analyses on PubMed ↗ · 243 randomized trials ↗
Conclusion: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
PubMed 26085043 ↗Conclusion: This systematic review and meta-analysis found that baloxavir probably reduced risk of hospital admission for high-risk patients and may reduce time to alleviation of symptoms, without increasing adverse events related to treatment in patients with nonsevere influenza. All other antiviral drugs either probably have little or no effect, or uncertain effects on patient-important outcomes.
PubMed 39804622 ↗Conclusion: On the basis of the results of this literature review, the authors recommend avoiding benzodiazepines and haloperidol for treating agitation and/or aggression in the context of TBI. Atypical antipsychotics (olanzapine in particular) can be considered as practical alternatives for the as-needed management of agitation and/or aggression in lieu of benzodiazepines and haloperidol. Amantadine, β-blockers (propranolol and pindolol), antiepileptics, and methylphenidate can be considered for scheduled treatment of agitation and/or aggression in patients with TBI.
PubMed 33656478 ↗337 human trials on ClinicalTrials.gov test Amantadine — 198 completed, 22 recruiting now. See all on ClinicalTrials.gov ↗
- Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients · Dementia
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases · Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain · 2019
- Prophylaxis of Neuropathic Pain by mémantine · Neuropathic Pain · 2013
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
The current US prescription label has no boxed warning.
9 recalls of products named for Amantadine. Most recent:
- 2026-03-04 · Class II: Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution. record ↗
- 2023-06-07 · Class II: CGMP Deviations: Firm went out of business and could no longer continue stability studies. record ↗
- 2021-06-02 · Class II: CGMP Deviations: Intermittent exposure to temperature excursion during storage. record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
20,181 adverse-event reports mention Amantadine. Most often reported:
- Fall · 2,155
- Hallucination · 1,556
- Drug ineffective · 1,519
- Fatigue · 1,405
- Dyskinesia · 1,277
- Gait disturbance · 1,186
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Amantadine E — an unlikely cause of liver injury. LiverTox entry ↗
NIH has funded 19 research projects with Amantadine in the title, $10,149,745 in total (1985–2017). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Amantadine ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I'm finding it effective personally at 150mg 2x a day. Although it feels like I'll need 200 to be effective by itself.”
“Amantadine has worked the best so far me but then after 2 year use, I feel like It didn't do much.”
“Only one thing ive heard about here that actually gave me relief from adhd symptoms and its amantadine”
Top discussions (5)
- Prefrontal cortex neuroplasticity ↗
- Nicotine normalizes brain activity deficits that are key to schizophrenia ↗
- Does anyone else now think nootropics are largely just a cope? ↗
- Do ADHD folk get better results from some nootropics? ↗
- I quit opioids and NSAIDs to start Ipamorelin and I’ve had blistering headaches for a month...could peptides help? ↗
Amantadine compared
Other options for focus
Sources
- User reports: 21 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate